IMPRIMIS PHARMACEUTICALS INC's ticker is IMMY and the CUSIP is 45323A201. A total of 2 filers reported holding IMPRIMIS PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $252,000 | +34.8% | 44,300 | -33.9% | 0.00% | – |
| Q3 2018 | $187,000 | +26.4% | 67,013 | 0.0% | 0.00% | – |
| Q2 2018 | $148,000 | +25.4% | 67,013 | 0.0% | 0.00% | – |
| Q1 2018 | $118,000 | +156.5% | 67,013 | +145.8% | 0.00% | – |
| Q4 2017 | $46,000 | +43.8% | 27,263 | +36.8% | 0.00% | – |
| Q3 2017 | $32,000 | -50.0% | 19,927 | -1.0% | 0.00% | – |
| Q2 2017 | $64,000 | -23.8% | 20,127 | 0.0% | 0.00% | – |
| Q1 2017 | $84,000 | -27.0% | 20,127 | -56.2% | 0.00% | – |
| Q4 2016 | $115,000 | -33.5% | 45,928 | +1.0% | 0.00% | – |
| Q3 2016 | $173,000 | +5.5% | 45,467 | +4.1% | 0.00% | – |
| Q2 2016 | $164,000 | -5.7% | 43,667 | 0.0% | 0.00% | – |
| Q1 2016 | $174,000 | -42.4% | 43,667 | 0.0% | 0.00% | – |
| Q4 2015 | $302,000 | +89.9% | 43,667 | +76.2% | 0.00% | – |
| Q3 2015 | $159,000 | – | 24,789 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,722,000 | $9,798,000 | 3.66% |
| Diametric Capital, LP | 252,160 | $1,453,000 | 1.12% |
| Birchview Capital, LP | 180,000 | $1,024,000 | 0.97% |
| EAM Global Investors LLC | 206,445 | $1,175,000 | 0.64% |
| EAM Investors, LLC | 301,415 | $1,715,000 | 0.47% |
| BARD ASSOCIATES INC | 51,550 | $293,000 | 0.17% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 85,569 | $487,000 | 0.11% |
| ARDSLEY ADVISORY PARTNERS LP | 75,000 | $427,000 | 0.11% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 112,859 | $642,000 | 0.04% |
| ELLINGTON MANAGEMENT GROUP LLC | 16,500 | $94,000 | 0.03% |